Elm Street Ventures

Founded in 2009 by Yale scientists and a chemical industry veteran, P2 Science is a venture-backed company specializing in renewable specialty chemicals. It converts renewable feedstocks like vegetable oils into high-value products such as flavor, fragrance, and cosmetics ingredients, serving diverse markets including food, personal care, and industrial cleaning.

Allyx Therapeutics, Inc. is a clinical-stage biotechnology company founded in 2018 and based in Durham, Connecticut. The company specializes in developing disease-modifying treatments for Alzheimer's Disease, with a focus on reversing neurodegeneration. Its lead product is an orally bioavailable small molecule that functions as a silent allosteric modulator of mGluR5. This innovative approach aims to provide clinicians with a therapeutic option capable of preserving cognition in patients while addressing the underlying disease mechanisms.

Cybrexa Therapeutics is a biotechnology company focused on developing an innovative class of small molecule DNA repair inhibitors aimed at improving cancer treatment. Founded in 2016 and based in New Haven, Connecticut, Cybrexa utilizes a proprietary peptide-based technology that specifically targets the tumor microenvironment. This approach allows for enhanced drug delivery and increased therapeutic efficacy, particularly when combined with existing chemotherapies and radiotherapies. By enabling the safe administration of higher drug doses, Cybrexa's therapeutics aim to expand the efficacy of current anticancer agents and address significant unmet medical needs in oncology. The company's novel platform has the potential to redefine drug delivery paradigms and enhance patient outcomes in cancer care.

Artizan Biosciences, Inc. is a biotechnology company focused on developing small molecule drugs for human use, particularly targeting diseases linked to intestinal inflammation. Founded in 2016 and headquartered in New Haven, Connecticut, the company employs its proprietary IgA-SEQ technology platform to identify and characterize disease-driving bacteria within the intestinal microbiota. This innovative approach aims to create precision therapeutics that address the root causes of various serious conditions, including digestive disorders, obesity, autoimmune diseases, and a range of other health issues affecting the skin, lungs, and central nervous system. By focusing on unmet medical needs, Artizan Biosciences seeks to provide novel treatment options for patients.

Founded in 2009 by Yale scientists and a chemical industry veteran, P2 Science is a venture-backed company specializing in renewable specialty chemicals. It converts renewable feedstocks like vegetable oils into high-value products such as flavor, fragrance, and cosmetics ingredients, serving diverse markets including food, personal care, and industrial cleaning.

Artizan Biosciences, Inc. is a biotechnology company focused on developing small molecule drugs for human use, particularly targeting diseases linked to intestinal inflammation. Founded in 2016 and headquartered in New Haven, Connecticut, the company employs its proprietary IgA-SEQ technology platform to identify and characterize disease-driving bacteria within the intestinal microbiota. This innovative approach aims to create precision therapeutics that address the root causes of various serious conditions, including digestive disorders, obesity, autoimmune diseases, and a range of other health issues affecting the skin, lungs, and central nervous system. By focusing on unmet medical needs, Artizan Biosciences seeks to provide novel treatment options for patients.

Saphlux, Inc. is a company based in New Haven, Connecticut, that specializes in the development, production, and commercialization of advanced semi-polar gallium nitride (GaN) materials. Founded in 2014, Saphlux addresses critical challenges in LED and laser technology, specifically targeting droop and green gap issues. The company offers semi-polar GaN templates in various sizes and is known for its innovative quantum dot (QD) technology integrated into micro-LED solutions. Saphlux designs and manufactures micro-LED chips and micro-display modules, including the NPQD R1 chip for public information displays and the NPQD T1 micro-display for augmented reality glasses. With a focus on enhancing output power and performance while reducing costs, Saphlux operates on a global scale, serving markets in the United States, China, and Japan.

Founded in 2009 by Yale scientists and a chemical industry veteran, P2 Science is a venture-backed company specializing in renewable specialty chemicals. It converts renewable feedstocks like vegetable oils into high-value products such as flavor, fragrance, and cosmetics ingredients, serving diverse markets including food, personal care, and industrial cleaning.

SeeClickFix is a platform that enables residents to report non-emergency issues and helps governments track, manage, and respond to requests, promoting transparency and collaboration in local governance. The company offers tools for request management, work management, citizen engagement, and data analytics to improve data collection, service delivery, and reporting to stakeholders. Its backend centralizes every reported issue, while its mobile app brings city information into residents’ hands and its dashboards support data-driven decisions. SeeClickFix serves municipalities and educational institutions by facilitating issue reporting, service coordination, and public accountability, enabling officials to evaluate performance, plan improvements, and communicate outcomes to communities.

Device42, Inc. is a software company that specializes in providing solutions for system, network, and data center engineers, as well as IT managers. Founded in 2010 and headquartered in West Haven, Connecticut, with an additional office in Boston, Massachusetts, Device42 offers a comprehensive suite of tools designed for IT inventory management, patch panel cable management, data center power management, and IP address tracking. Its platform includes essential features such as Configuration Management Database (CMDB), Application Dependency Mapping (ADM), and a DCIM Software Marketplace, all aimed at helping organizations maintain accurate inventories of both IP-based and non-IP assets. The software facilitates various IT operations, compliance auditing, migration, and modernization processes, making it easier for clients to manage hybrid IT environments and execute successful cloud migrations while ensuring compliance with internal and external regulations.

Device42, Inc. is a software company that specializes in providing solutions for system, network, and data center engineers, as well as IT managers. Founded in 2010 and headquartered in West Haven, Connecticut, with an additional office in Boston, Massachusetts, Device42 offers a comprehensive suite of tools designed for IT inventory management, patch panel cable management, data center power management, and IP address tracking. Its platform includes essential features such as Configuration Management Database (CMDB), Application Dependency Mapping (ADM), and a DCIM Software Marketplace, all aimed at helping organizations maintain accurate inventories of both IP-based and non-IP assets. The software facilitates various IT operations, compliance auditing, migration, and modernization processes, making it easier for clients to manage hybrid IT environments and execute successful cloud migrations while ensuring compliance with internal and external regulations.

Founded in 2009 by Yale scientists and a chemical industry veteran, P2 Science is a venture-backed company specializing in renewable specialty chemicals. It converts renewable feedstocks like vegetable oils into high-value products such as flavor, fragrance, and cosmetics ingredients, serving diverse markets including food, personal care, and industrial cleaning.

Arvinas, Inc. is a clinical-stage biopharmaceutical company based in New Haven, Connecticut, that specializes in the discovery, development, and commercialization of innovative therapies aimed at degrading disease-causing proteins. The company's lead product candidates include ARV-110, a proteolysis targeting chimera (PROTAC) currently in phase I clinical trials for metastatic castration-resistant prostate cancer, and ARV-471, which targets the estrogen receptor for patients with metastatic ER-positive/HER2-negative breast cancer. In addition to these, Arvinas is developing various other PROTACs aimed at degrading clinically relevant androgen receptor mutations and treatments for neurodegenerative diseases, including tauopathies. The company has established collaborations with prominent pharmaceutical firms such as Pfizer Inc., Genentech, and Bayer AG, enhancing its research capabilities and reach within the biopharmaceutical landscape. Founded in 2015, Arvinas aims to improve patient outcomes by eliminating harmful proteins from the body through its proprietary technology.

Founded in 2009 by Yale scientists and a chemical industry veteran, P2 Science is a venture-backed company specializing in renewable specialty chemicals. It converts renewable feedstocks like vegetable oils into high-value products such as flavor, fragrance, and cosmetics ingredients, serving diverse markets including food, personal care, and industrial cleaning.

Accelerated Orthopedic Technologies, Inc. is a Guilford, Connecticut-based company that specializes in developing proprietary instruments for the treatment of articular cartilage defects. The company offers custom sizes, shapes, and matching topography for cartilage grafts, which are essential for addressing joint-related issues. Founded in 2009 and initially known as Advanced Orthopedic Technologies, the company rebranded to its current name in February 2010. Through its innovative approach, Accelerated Orthopedic Technologies aims to improve surgical outcomes and enhance patient care in orthopedic procedures.

Kolltan Pharmaceuticals, Inc. is a clinical-stage biotechnology company founded in 2007 and based in New Haven, Connecticut. The company specializes in the discovery and development of monoclonal antibody drugs that target receptor tyrosine kinases (RTKs), which play a crucial role in various cancers and other diseases. Its lead product candidate, KTN3379, is an antibody targeting the ErbB3 RTK and is currently undergoing Phase I clinical trials for adult patients with advanced solid tumors. Additionally, Kolltan is developing KTN0158, a KIT RTK inhibitor aimed at treating neurofibromatosis type 1 and other inflammatory conditions, as well as KIT-ADC, an antibody-drug conjugate for oncology applications. The company is also engaged in various research programs focused on RTK targets, building on foundational discoveries made in collaboration with leading academic laboratories. As of late 2016, Kolltan Pharmaceuticals operates as a subsidiary of Celldex Therapeutics, Inc.

BioRelix, Inc., a biopharmaceutical company, engages in the discovery and development of anti-biotic drug candidates for the treatment of infectious diseases in the United States. It develops a portfolio of riboswitch-based therapeutic agents to overcome the lethal and devastating causes of bacterial infections. The company was founded in 2005 and is based in New Haven, Connecticut.